Study study type PathologyT1T0Patientssample sizesROB Results deaths (OS) Eprogression or deaths (PFS) ERFS/DFS E

mHNSCC - L2 - PDL1 negative metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - PDL1 negative

versus durvalumab alone
durvalumab plus tremelimumab
CONDOR (DT vs D ; PDL1 TC<25%), 2019
  NCT02319044
RCTmHNSCC - L2 - PDL1 negativedurvalumab plus tremelimumabdurvalumab monotherapypatients with recurrent or metastatic HNSCC (PD-L1-low/negative) that had progressed after 1 platinum-containing regimen in the R/M setting133 / 67high
inconclusive -1% 13%
versus tremelimumab
durvalumab plus tremelimumab
CONDOR (DT vs T ; PDL1 TC<25%), 2019
  NCT02319044
RCTmHNSCC - L2 - PDL1 negativedurvalumab plus tremelimumabtremelimumab monotherapypatients with recurrent or metastatic HNSCC (PD-L1-low/negative) that had progressed after 1 platinum-containing regimen in the R/M setting133 / 67high
suggested -28% -27%